#approvals 2022

[amcrasto]

Pamiparib

Pamiparib BGB-290 APPROVED CHINA 2022, BEIGENE (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one 1446261-44-4 8375F9S90C 5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)- 5,6,7a,11-Tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one,…

View On WordPress

[amcrasto]

AZVUDINE

AZVUDINE CAS 1011529-10-4 WeightAverage: 286.223Monoisotopic: 286.082581021 Chemical FormulaC9H11FN6O4 FNC HY-19314 RO 0622 RO-0622 SB17040 IJ2XP0ID0K DTXSID901027757 4-amino-1-[(2R,3S,4R,5R)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one 2′-Deoxy-2′-beta-fluoro-4′-azidocytidine 2(1H)-Pyrimidinone,…

View On WordPress

[amcrasto]

Adagrasib

Adagrasib FormulaC32H35ClFN7O2cas 2326521-71-3Mol weight604.1174 Antineoplastic  DiseaseNon-small cell lung cancer 2022/12/12 FDA APPROVED, KRAZATI (Mirati Therapeutics) MRTX-849 MRTX849 KRAS G12C inhibitor MRTX849 Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer.[1][2] Adagrasib is an inhibitor of the RAS GTPase…

View On WordPress

[amcrasto]

Nirsevimab

(Heavy chain)QVQLVQSGAE VKKPGSSVMV SCQASGGLLE DYIINWVRQA PGQGPEWMGG IIPVLGTVHYGPKFQGRVTI TADESTDTAY MELSSLRSED TAMYYCATET ALVVSETYLP HYFDNWGQGTLVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFPAVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPAPELLGGPSVF LFPPKPKDTL YITREPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKPREEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG…

View On WordPress

[amcrasto]

Olutasidenib

Olutasidenib FT-2102 FT2102 C18H15ClN4O2 354.79 CAS1887014-12-1 Rezlidhia (Forma Therapeutics) SYN Caravella JA, et al. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. J Med Chem. 2020 Feb 27;63(4):1612-1623. doi: 10.1021/acs.jmedchem.9b01423. Epub 2020 Feb 12. FDA 12/1/2022, To treat adults with relapsed or refractory acute…

View On WordPress

[amcrasto]

Mirvetuximab soravtansine-gynx

Mirvetuximab soravtansine-gynx FDA 11/14/2022, To treat patients with rTo treat patients with recurrent ovarian cancer that is resistant to platinum therapy that is resistant to platinum therapy,  Elahere FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer https://www.biochempeg.com/article/315.html 4846-85a8-48171ab38275 FDA Approves Mirvetuximab…

View On WordPress

[amcrasto]

Tremelimumab

(Light chain)DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP GKAPKLLIYA ASSLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP GTKVEIKRTV AAPSVFIFPPSDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLTLSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC(Heavy chain)QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP RGATLYYYYY GMDVWGQGTTVTVSSASTKG…

View On WordPress

[amcrasto]

Ozoralizumab

Ozoralizumab FormulaC1682H2608N472O538S12CAS 1167985-17-2Mol weight38434.3245  PMDA JAPAN  APPROVED 2022 2022/9/26 Nanozora anti-TNFα Nanobody®; ATN-103; Nanozora; PF-5230896; TS-152 Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to…

View On WordPress